Brief: Palisade Bio's LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
24/05/2023 13:48
May 24 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO’S LB1148 TWO ONGOING CLINICAL TRIALS
EXPECTING
TOPLINE DATA READOUTS
* PALISADE BIO INC - EXPECTS TO COMPLETE ENROLLMENT AND
REPORT
TOPLINE DATA IN Q3 2023 FOR DOSE OPTIMIZATION STUDY
* PALISADE BIO INC - EXPECTS TO REPORT TOPLINE DATA WITHIN
FOUR
WEEKS FOLLOWING LAST SURGERY FOR U.S. PHASE 2 ADHESIONS STUDY
Source text for Eikon: ID:nGNX1WyQvR
Further company coverage: PALI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing